Linked Life Data

3261249

Source:http://linkedlifedata.com/resource/pubmed/id/3261249

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
1988-9-16
pubmed:abstractText
Monkeys developed a severe parkinsonian syndrome after intravenous administration of (MPTP). L-DOPA/carbidopa (D-1 and D-2) or bromocriptine (D-2) treatment relieved the parkinsonian symptoms, whereas SKF 38393 (D-1) was ineffective. No dyskinesia was seen in monkeys receiving bromocriptine or SKF 38393 as opposed to the L-DOPA-treated animals, in which the dyskinetic response appeared to increased with time. MPTP induced a significant increase (25%, P less than 0.01) in the number of [3H]spiperone binding sites (Bmax) in the caudate nucleus and in putamen. The Bmax of spiperone binding in the L-DOPA-treated monkeys was on average 18% lower (P less than 0.01) than that of the animals treated with MPTP alone. The Bmax for the bromocriptine-treated group was 29% (P less than 0.01) less than that in the MPTP-treated group or 11% (P less than 0.05) less than that in the L-DOPA-treated monkeys. The SKF 38393 treatment induced a 23% (P less than 0.01) decrease in the Bmax as compared to that of animals treated with MPTP alone, and no significant change compared to the L-DOPA- or bromocriptine-treated animals. These results suggest that stimulation of D-1 and D-2 dopamine receptors can differently influence the mechanisms controlling dopamine agonist-induced dyskinesia in MPTP-treated monkeys.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0014-2999
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
150
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
59-66
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:3261249-1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, pubmed-meshheading:3261249-2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine, pubmed-meshheading:3261249-3,4-Dihydroxyphenylacetic Acid, pubmed-meshheading:3261249-Animals, pubmed-meshheading:3261249-Apomorphine, pubmed-meshheading:3261249-Benzazepines, pubmed-meshheading:3261249-Brain Chemistry, pubmed-meshheading:3261249-Dopamine, pubmed-meshheading:3261249-Dyskinesia, Drug-Induced, pubmed-meshheading:3261249-Female, pubmed-meshheading:3261249-Homovanillic Acid, pubmed-meshheading:3261249-Macaca fascicularis, pubmed-meshheading:3261249-Motor Activity, pubmed-meshheading:3261249-Parkinson Disease, Secondary, pubmed-meshheading:3261249-Pyridines, pubmed-meshheading:3261249-Receptors, Dopamine, pubmed-meshheading:3261249-Spiperone
pubmed:year
1988
pubmed:articleTitle
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
pubmed:affiliation
School of Pharmacy, Laval University, Québec, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't